ATE206432T1 - A3 -adenosin -rezeptor agonisten - Google Patents

A3 -adenosin -rezeptor agonisten

Info

Publication number
ATE206432T1
ATE206432T1 AT94923445T AT94923445T ATE206432T1 AT E206432 T1 ATE206432 T1 AT E206432T1 AT 94923445 T AT94923445 T AT 94923445T AT 94923445 T AT94923445 T AT 94923445T AT E206432 T1 ATE206432 T1 AT E206432T1
Authority
AT
Austria
Prior art keywords
receptor
adenosine receptor
mammal
uronamide
provides
Prior art date
Application number
AT94923445T
Other languages
English (en)
Inventor
Kenneth A Jacobson
Carola Gallo-Rodriguez
Galen Philip J M Van
Lubitz Dag K J E Von
Heaok Kim Jeong
Seodaemun-Ku College Of P Dong
Original Assignee
Nasa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nasa filed Critical Nasa
Application granted granted Critical
Publication of ATE206432T1 publication Critical patent/ATE206432T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT94923445T 1993-07-13 1994-07-13 A3 -adenosin -rezeptor agonisten ATE206432T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9110993A 1993-07-13 1993-07-13
US16332493A 1993-12-06 1993-12-06
PCT/US1994/007835 WO1995002604A1 (en) 1993-07-13 1994-07-13 A3 adenosine receptor agonists

Publications (1)

Publication Number Publication Date
ATE206432T1 true ATE206432T1 (de) 2001-10-15

Family

ID=26783598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94923445T ATE206432T1 (de) 1993-07-13 1994-07-13 A3 -adenosin -rezeptor agonisten

Country Status (6)

Country Link
US (1) US5773423A (de)
EP (1) EP0708781B1 (de)
AT (1) ATE206432T1 (de)
AU (1) AU7331094A (de)
DE (1) DE69428536T2 (de)
WO (1) WO1995002604A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
AU2603197A (en) 1996-04-10 1997-10-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of an a1 adenosine receptor agonist to treat cerebral ischaemia
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
US5888532A (en) * 1996-08-16 1999-03-30 Pritsos; Chris A. Treatment of alcoholism and related disorders with (nicotinamide-adenine dinucleotide) phosphate derivatives
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2295195C (en) 1997-06-18 2009-12-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US20020058669A1 (en) * 1998-06-15 2002-05-16 Herman H. P. M. Van Helden Process for the treatment of organophosphate poisoning
US6495528B1 (en) 1998-06-23 2002-12-17 Smithkline Beecham Corporation 2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2336967C (en) 1998-07-10 2010-06-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
WO2001051490A1 (en) 2000-01-14 2001-07-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
US20010051348A1 (en) 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
CN1259056C (zh) * 2001-01-16 2006-06-14 坎-菲特生物药物有限公司 腺苷a3受体激动剂用于抑制病毒复制的用途
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
EP1241176A1 (de) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purinderivate zur Behandlung von Ischämie
JP2002338593A (ja) 2001-05-22 2002-11-27 Ajinomoto Co Inc β−Ｄ−リボフラノース誘導体又はその光学異性体の製造方法
US6921594B2 (en) * 2001-12-19 2005-07-26 Sud-Chemie Inc. Exhaust treatment and filtration system for molten carbonate fuel cells
US6846988B2 (en) * 2002-01-18 2005-01-25 Adc Telecommunications, Inc. Triaxial connector including cable clamp
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
WO2004045627A1 (en) * 2002-11-19 2004-06-03 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
CZ294538B6 (cs) * 2002-12-30 2005-01-12 Ústav Experimentální Botaniky Akademie Vědčeské Re Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
US20050101560A1 (en) * 2003-11-12 2005-05-12 Can-Fite Biopharma Ltd. Method of treating an individual with methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl] beta-D-ibofuronamide
EP1699459B1 (de) * 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Verfahren zur behandlung von multipler sklerose
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US7423144B2 (en) 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
JP4642847B2 (ja) * 2004-07-28 2011-03-02 キャン−ファイト・バイオファーマ・リミテッド シェーグレン症候群を含むドライアイ疾患治療用アデノシンａ３レセプターアゴニスト
CN101056879B (zh) * 2004-09-09 2011-10-05 美国政府卫生与公共服务部 作为a3和a1腺苷受体激动剂的嘌呤衍生物
AU2005286946B2 (en) 2004-09-20 2012-03-15 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
US20080051364A1 (en) * 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
CA2596142A1 (en) * 2005-02-04 2006-08-10 Uti Limited Partnership Adenosine analogs useful as anti-bacterial and anti-protozoan agents
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20080300213A1 (en) 2005-11-30 2008-12-04 Pnina Fishman Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment
EA015683B1 (ru) 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
EP2010534A4 (de) * 2006-04-13 2010-08-18 Astrazeneca Ab Thioxanthinderivate und ihre verwendung als mpo-inhibitoren
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
US7893227B2 (en) * 2006-12-05 2011-02-22 Lasergen, Inc. 3′-OH unblocked nucleotides and nucleosides base modified with non-cleavable, terminating groups and methods for their use in DNA sequencing
US7897737B2 (en) * 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
US9102698B2 (en) 2007-03-14 2015-08-11 Can-Fite Biopharma Ltd. Process for the synthesis of IB-MECA
WO2009006046A1 (en) 2007-06-29 2009-01-08 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the gpcr superfamily
DK2227234T3 (da) * 2007-10-15 2014-08-11 Can Fite Biopharma Ltd Fremgangsmåde til induktion af hepatocytproliferering og anvendelserderaf
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
EP2260038B1 (de) 2008-03-31 2014-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purinderivate als selektive agonisten des adenosin-rezeptors a3
CN102264917B (zh) 2008-06-11 2015-06-10 激光基因公司 核苷酸和核苷以及将其用于dna测序的方法
AU2009276411B2 (en) * 2008-08-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
AU2010250759B2 (en) 2009-05-17 2013-03-14 Can-Fite Biopharma Ltd. A3 adenosine receptor agonists for the reduction of intraocular pressure
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
EP2507241A1 (de) 2009-12-02 2012-10-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosin-derivate und dendrimerkonjugate daraus
LT2523669T (lt) 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
US20130045943A1 (en) 2010-03-03 2013-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of A3ar agonists for the treatment of uveitis
CA2792266A1 (en) 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using n6-cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
EP2583972B1 (de) * 2010-06-18 2018-04-18 Hayashibara Co., Ltd. Therapeutikum für entzündungskrankheiten mit adenosin-n1-oxid als wirkstoff
WO2012100654A1 (zh) * 2011-01-26 2012-08-02 北京化工大学 呋喃核糖基嘌呤类化合物及其制备方法和应用
CN102617680B (zh) * 2011-02-01 2014-04-02 复旦大学 一种双功能抗血小板聚集药物及其用途
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
CA2848049C (en) 2011-09-13 2021-01-26 Lasergen, Inc. 5-methoxy, 3'-oh unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing
PL2807178T3 (pl) 2012-01-26 2017-12-29 Inotek Pharmaceuticals Corporation Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
CN103421067A (zh) * 2012-05-18 2013-12-04 复旦大学 一种双靶点抗血小板聚集药物及其用途
WO2014024195A1 (en) 2012-08-09 2014-02-13 Can-Fite Biopharma Ltd. A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
WO2014152723A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
JP2015172077A (ja) * 2015-06-24 2015-10-01 中国医学科学院葯物研究所 Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
KR102445887B1 (ko) 2016-04-21 2022-09-21 아스트로사이트 파마슈티컬스, 인코포레이티드 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법
CN106632333A (zh) * 2016-11-30 2017-05-10 湖州恒远生物化学技术有限公司 一种低成本8‑氯茶碱的制备方法
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
CN109666053A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 一种a3腺苷受体激动剂及其用途
WO2019105388A1 (zh) * 2017-11-29 2019-06-06 苏州科睿思制药有限公司 一种a3腺苷受体激动剂药物的晶型及其制备方法和用途
CN112218638A (zh) 2018-02-09 2021-01-12 阿斯特罗赛特制药公司 用于治疗成瘾和相关病症的化合物和方法
EP3856741A4 (de) 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. Polymorphe verbindungen und verwendungen davon
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina Adenosine a3 receptor ligand for use in lowering adipocyte levels
EP4273153A4 (de) * 2020-12-29 2024-05-08 Zhejiang Vimgreen Pharmaceuticals, Ltd Adenosin-a3-rezeptoragonisten, herstellungsverfahren und verwendungen davon
IT202300014340A1 (it) 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.
IT202300020286A1 (it) 2023-10-02 2025-04-02 Procos Spa Processo per la sintesi di piclidenoson a partire dall’adenosina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6717061A (de) * 1966-12-21 1968-06-24
DE2524284A1 (de) * 1966-12-21 1976-10-28 Boehringer Mannheim Gmbh Adenosin-derivate und verfahren zu ihrer herstellung
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US5140015A (en) * 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage

Also Published As

Publication number Publication date
WO1995002604A1 (en) 1995-01-26
US5773423A (en) 1998-06-30
EP0708781B1 (de) 2001-10-04
AU7331094A (en) 1995-02-13
EP0708781A1 (de) 1996-05-01
DE69428536D1 (de) 2001-11-08
DE69428536T2 (de) 2002-06-06

Similar Documents

Publication Publication Date Title
DE69428536D1 (de) A3 -adenosin -rezeptor agonisten
DK0725782T3 (da) A1-adenosin-receptor-agonister og antiagonister
FI882791A7 (fi) Aineita, jotka parantavat määrättyjen 1,4-dihydropyridiinijohdannaisten siirtymistä ihon läpi.
BR0109107A (pt) Usos terapêuticos de mediadores ppar
SE0003984L (sv) Adenosin A3-receptormodulatorer
IT8621358A0 (it) Composizione farmaceutica adattivita' analgesica.
BR9612324A (pt) "agonistas e antagonistas receptores de adenosina a"
IT8323205A0 (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
FI943817A7 (fi) Bisyklo/2.2.2/oktaanijohdannaisia kolestokystokiniinin inhibiittoreina
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
DE3887839D1 (de) Trennmittelzusammensetzung.
DE69004256D1 (de) Dihydropyrimidin-antiallergie-mittel.
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
NO943846L (no) Angiotensin II antagonister mot forstyrrelser knyttet til svekket nerveledningshastighet, særlig diabetisk nevropati
BR9608594B1 (pt) misturas de benzimidazóis substituìdos para o combate de protozoários parasìticos.
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
DK630589D0 (da) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor-sammensaetning
ES2106025T3 (es) Analogos de gangliosidos semisinteticos.
ATE113949T1 (de) Alpha-adrenergische rezeptorantagonisten.
UA26443A (uk) Похідhі 20,21-диhоребурhамеhіhу, їх рацемати або оптичhі ізомери, або їх адитивhі солі з оргаhічhими кислотами, що мають hоотропhі та аhтидепресивhі властивості
IT8119758A0 (it) Derivati 2'-deossi-3',5'-di-o-alchilcarbonil-5-fluorouri dinici processo per la loro preparazione e agenti antitumorali che contengono i detti derivati.
DE69001580D1 (de) Perkutane verabreichung von 3'-azido-3'-deoxythymidin.
IT8821570A0 (it) Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante.
DK316188A (da) Sulfolipopolysaccharider som stimolatorer for den ikke specifikke forsvarsmekanisme
FI955257A0 (fi) 8-substituoidut-ksantiinit valikoivina adenosiinireseptoriaineina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties